A Study to Assess the Abuse Potential of Intranasal Cebranopadol (clinicaltrials.gov) - Dec 13, 2024 - P1 | N=45 | Active, not recruiting | Sponsor: Tris Pharma, Inc. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Addiction (Opioid and Alcohol)
|